The FDA approval expands the use of marstacimab-hncq (Hympavzi; Pfizer Inc.) for routine prophylaxis to prevent or reduce bleeding episodes in additional pediatric and inhibitor-positive hemophilia A and B...
A randomized clinical trial evaluating 2 types of 1-page educational resources for low back pain found that fact sheets listing treatment options modestly improved patients’ preparedness for shared...
In a resting-state fMRI study of adults with episodic migraine, chronic migraine, and healthy controls, migraine was associated with reduced brain entropy, with partial entropy restoration during attacks.
...
In a cross-sectional questionnaire study of 106 adults with migraine, vomiting-induced migraine pain relief occurred in 54.9% of patients who vomited during attacks, with some reporting pain relief within...
Improving TDF-FTC uptake among US young men who have sex with men on HIV PrEP could yield substantial 10-year value, while a hypothetical study eliminating adverse event uncertainty would not change the...
Featured faculty at The Revolution & Paradigm Shift in Treatment of Migraine, scheduled for July 16-17, 2026, will highlight evolving approaches to migraine diagnosis, prevention, disease burden, and...
The FDA has approved veligrotug-vvze (Lumvoa) for the treatment of thyroid eye disease regardless of disease activity or duration, based on the pivotal phase 3 THRIVE and THRIVE-2 clinical trials.
In two phase 3, double-blind, placebo-controlled trials of adults with noncirrhotic chronic hepatitis B virus infection receiving stable nucleoside or nucleotide analog therapy, 24 weeks of bepirovirsen...
In an international Bayesian adaptive RCT of adults with MSSA bacteremia, cefazolin was noninferior to flucloxacillin or cloxacillin for 90-day all-cause mortality and was associated with less acute kidney...
